

Anthony Marshall

From: hra.amendments@nhs.net <noreply@harp.org.uk>
Sent: 12 October 2018 16:03
To: Kimme Hyrich; MHS Ethics Applications
Cc: Anthony Marshall; research-permissions@wales.nhs.uk; nhsg.nrspcc@nhs.net; research.amendments@hscni.net
Subject: IRAS Project ID 64202. HRA Approval for the Amendment

Dear Dr Hyrich,

IRAS Project ID:	64202
Short Study Title:	Prospective observational study of the long-term hazards of anti-TNF therapy in rheumatoid arthritis
Amendment No./Sponsor Ref:	26
Amendment Date:	19 September 2018
Amendment Type:	Substantial Non-CTIMP

I am pleased to confirm **HRA and HCRW Approval** for the above referenced amendment.

You should implement this amendment at NHS organisations in England and Wales, in line with the conditions outlined in your categorisation email.

User Feedback

The Health Research Authority is continually striving to provide a high quality service to all applicants and sponsors. You are invited to give your view of the service you have received and the application procedure. If you wish to make your views known please use the feedback form available on the HRA website: <http://www.hra.nhs.uk/about-the-hra/governance/quality-assurance/>.

Please contact hra.amendments@nhs.net for any queries relating to the assessment of this amendment.

Kind regards

Mrs Kirsten Peck
HRA Approval Amendment Coordinator
Health Research Authority

Ground Floor | Skipton House | 80 London Road | London | SE1 6LH

[E.hra.amendments@nhs.net](mailto:hra.amendments@nhs.net)

[W. www.hra.nhs.uk](http://www.hra.nhs.uk)

Sign up to receive our newsletter [HRA Latest](#).